Regeneron Pharmaceuticals Inc. buy BiotechBee
Summary
This prediction ended on 05.05.23 with a price of €687.50. With a performance of -9.34%, the BUY prediction for Regeneron Pharmaceuticals Inc. by BiotechBee closed slightly in the red. BiotechBee has 70% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Regeneron Pharmaceuticals Inc. | -1.200% | -1.200% | 19.019% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% |
According to BiotechBee what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Cons
Comments by BiotechBee for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.